William Blair analyst Sami Corwin has maintained their bullish stance on QURE stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sami Corwin has given his Buy rating due to a combination of factors including uniQure’s strategic advancements in their clinical trials and regulatory progress. The initiation of a fourth cohort for the AMT-130 trial in Huntington’s disease patients, particularly those with lower striatal volume, demonstrates the company’s proactive approach in expanding their research scope. This move is expected to potentially broaden the applicability of their treatment, enhancing its market potential.
Additionally, the submission of a statistical analysis plan to the FDA and the anticipation of pivotal data from the Phase I/II trial of AMT-130 in September are significant milestones. These developments, coupled with the planned pre-BLA meeting with the FDA in 2025, indicate a clear pathway towards a Biologics License Application. Furthermore, the upcoming presentation of initial safety and efficacy data for AMT-191 in Fabry disease underscores uniQure’s commitment to diversifying their therapeutic pipeline, which could drive future growth.